Trial · NCT02883049
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) Interim Maintenance High-dose Methotrexate Backbone | Non-DS HR B-ALL Arm A | 92.48 | 95% Confidence Interval 90.7 to 94.3 | Percentage of patients | |
DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) Interim Maintenance High-dose Methotrexate Backbone | Non-DS HR B-ALL Arm B | 92.33 | 95% Confidence Interval 90.5 to 94.2 | Percentage of patients | |
DFS of Non-DS VHR Post-Induction Patients Who Receive a Modified MBFM-IMHDM Regimen That Contains a Second IM (Control Arm) Compared to Patients Receive the Cyclophosphamide + Etoposide Containing Regimen (Experimental Arm 1) | Non-DS VHR B-ALL Control Arm | 77.11 | 95% Confidence Interval 72.4 to 81.8 | Percentage of patients | |
DFS of Non-DS VHR Post-Induction Patients Who Receive a Modified MBFM-IMHDM Regimen That Contains a Second IM (Control Arm) Compared to Patients Receive the Cyclophosphamide + Etoposide Containing Regimen (Experimental Arm 1) | Non-DS VHR B-ALL Exp Arm1 | 76.75 | 95% Confidence Interval 72.8 to 80.7 | Percentage of patients | |
| Toxicity and Tolerability of Post-induction Age-adjusted ITT Compared to Age-adjusted IT MTX in Children With HR B-ALL | Non-DS HR B-ALL Arm A | 62.44 | 95% Confidence Interval 59.2 to 65.7 | Percentage of patients | |
| Toxicity and Tolerability of Post-induction Age-adjusted ITT Compared to Age-adjusted IT MTX in Children With HR B-ALL | Non-DS HR B-ALL Arm B | 63.39 | 95% Confidence Interval 60.2 to 66.6 | Percentage of patients | |
| Toxicity and Tolerability of Experimental Arm 1 and Control Arm in Patients With VHR B-ALL | Non-DS VHR B-ALL Control Arm | 66.27 | 95% Confidence Interval 61.2 to 71.3 | Percentage of patients | |
| Toxicity and Tolerability of Experimental Arm 1 and Control Arm in Patients With VHR B-ALL | Non-DS VHR B-ALL Exp Arm1 | 73.16 | 95% Confidence Interval 69.2 to 77.1 | Percentage of patients | |
| Induction Mortality in Patients With DS and HR B-ALL Treated With Modified Induction | DS HR B-ALL (Induction) | 3.57 | 95% Confidence Interval 1.1 to 6.0 | Percentage of patients | |
| 5-year DFS in Patients With Down Syndrome (DS) and HR B-ALL Treated With Modified Induction and Post-Induction Therapy Regimen With MBFM-IMIDM | DS HR B-ALL | 71.78 | 95% Confidence Interval 65.7 to 77.8 | Percentage of patients | |
| DFS for Children and Young Adults With Ph-like B-ALL and a Predicted Tyrosine Kinase Inhibitor (TKI)-Sensitive Mutation Treated With Dasatinib Plus MBFM-IMHDM | Non-DS Ph-like Pred TKI Sensitive Kinase Dasatinib Arm | 55.56 | 95% Confidence Interval 32.6 to 78.5 | Percentage of patients | |
| Toxicity and Tolerability of MBFM-interim Maintenance Intermediate Dose Methotrexate (IMIDM) in Children With Down Syndrome | DS HR B-ALL | 50 | 95% Confidence Interval 43.6 to 56.4 | Percentage of patients | |
| Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm | Non-DS HR B-ALL Overall | 96.65 | 95% Confidence Interval 95.8 to 97.5 | Percentage of patients | |
| Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm | Non-DS HR B-ALL Arm A | 97.05 | 95% Confidence Interval 95.9 to 98.2 | Percentage of patients | |
| Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm | Non-DS HR B-ALL Arm B | 96.25 | 95% Confidence Interval 94.9 to 97.6 | Percentage of patients | |
| Overall Survival (OS) Rate for VHR B-ALL Patients, Overall and by Randomized Arm. | Non-DS VHR B-ALL Overall | 87.87 | 95% Confidence Interval 85.6 to 90.1 | Percentage of patients | |
| Overall Survival (OS) Rate for VHR B-ALL Patients, Overall and by Randomized Arm. | Non-DS VHR B-ALL Control Arm | 87.31 | 95% Confidence Interval 83.6 to 91.1 | Percentage of patients | |
| Overall Survival (OS) Rate for VHR B-ALL Patients, Overall and by Randomized Arm. | Non-DS VHR B-ALL Experimental Arm 1 | 88.50 | 95% Confidence Interval 85.5 to 91.5 | Percentage of patients | |
| Incidence of Osteonecrosis (ON) Defined by Magnetic Resonance (MR) Imaging in Children, Adolescents, and Young Adults 10 Years of Age and Greater | HR and VHR B-ALL Patients (10 Years or Older) | 25 | 95% Confidence Interval 19.8 to 30.2 | Percentage of patients | |
| The Prevalence of Cognitive Deficits Measured by CogState (Domain: Working Memory), in Children (Ages 6 to < 13 Years) With HR- and VHR B-ALL at 1 Year Off Therapy | HR and VHR B-ALL Patients (6 to <13 Years Old) | 19.11 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02883049/results